LOGIN  |  REGISTER
Compass Therapeutics

Sonida Senior Living to Participate in the Morgan Stanley 8th Annual CRE Conference

February 06, 2025 | Last Trade: US$26.47 0.33 1.26

DALLAS / Feb 06, 2025 / Business Wire / Sonida Senior Living, Inc. (“Sonida” or the “Company”) (NYSE: SNDA), a leading owner, operator and investor in senior living communities, announced today that Brandon Ribar, President & Chief Executive Officer, Kevin Detz, Chief Financial Officer and Max Levy, Chief Investment Officer, will participate in Morgan Stanley’s Annual Commercial Real Estate Conference on Wednesday, February 19th and Thursday, February 20th at the Morgan Stanley Headquarters in New York City.

Management will be available for one-on-one meetings with institutional investors during the conference. To schedule a meeting, please contact your bank representative.

In addition, Mr. Ribar is scheduled to participate in a moderated panel discussion entitled “Longevity and Senior Living,” on Wednesday, February 19th from 10:15 a.m. – 10:55 a.m. EST.

About Sonida

Dallas-based Sonida Senior Living, Inc. is a leading owner, operator and investor in independent living, assisted living and memory care communities and services for senior adults. The Company provides compassionate, resident-centric services and care as well as engaging programming operating 94 senior housing communities in 20 states with an aggregate capacity of over 10,000 residents, including 81 communities which the Company owns (including eight communities in which the Company owns varying interests through two separate joint ventures), and 13 communities that the Company manages on behalf of a third-party.

For more information, visit www.sonidaseniorliving.com or connect with the Company on Facebook, X or LinkedIn. 

Terns Pharmaceuticals

Stock Quote

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page